Future Oncology
Overview
Future Oncology is a peer-reviewed journal dedicated to advancing the understanding and treatment of cancer. It provides a platform for cutting-edge research, clinical trials, and expert opinions on emerging therapies, diagnostics, and personalized medicine. With a focus on the future of oncology, this journal aims to improve patient outcomes and shape the direction of cancer care worldwide.
Details
Details
Abbr.
Future Oncol
Start
2005
End
Continuing
Frequency
Forty no. a year, 2022-
p-ISSN
1479-6694
e-ISSN
1744-8301
Country
United Kingdom
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 3682
90
SJR / Ranks: 3629
1029
CiteScore / Ranks: 4778
5.20
JIF / Ranks: 3040
3.3
Recent Articles
1.
Nagasaka M, Roy U, Berk A, Liu G, Nadler E, Abrahami D
Future Oncol
. 2025 Mar;
:1-7.
PMID: 40084656
With the ongoing discovery of various oncogenic driver mutations in metastatic non-small cell lung cancer (mNSCLC), a precision medicine approach has emerged, characterized by targeted therapies for select patient populations....
2.
Kasper B, Whiting J, Lawson D, Portnoy M, Schuster K, Baumgarten C, et al.
Future Oncol
. 2025 Mar;
:1-13.
PMID: 40070345
No abstract available.
3.
Shore N, George D, Spratt D, De La Cerda J
Future Oncol
. 2025 Mar;
:1-5.
PMID: 40051382
Relugolix is a once-daily oral gonadotropin-releasing hormone antagonist that was approved by the U.S. Food and Drug Administration in 2020 for the treatment of advanced prostate cancer. Relugolix is commonly...
4.
Janne P, Planchard D, Kobayashi K, Cheng Y, Lee C, Valdiviezo N, et al.
Future Oncol
. 2025 Mar;
:1-12.
PMID: 40051276
No abstract available.
5.
Garcia-Manero G, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, et al.
Future Oncol
. 2025 Mar;
:1-13.
PMID: 40051275
No abstract available.
6.
Castro E, Wang D, Walsh S, Craigie S, Haltner A, Nazari J, et al.
Future Oncol
. 2025 Mar;
:1-10.
PMID: 40045559
Aims: The absence of direct comparisons between talazoparib plus enzalutamide (TALA+ENZA) and current standard of care hinders evaluating their relative efficacy for first-line (1 L) metastatic castration resistant prostate cancer...
7.
Rugo H, Schmid P, Tolaney S, Marme F, Bardia A, Spears P, et al.
Future Oncol
. 2025 Mar;
21(7):775-786.
PMID: 40045471
No abstract available.
8.
Borque-Fernando A, Alonso-Gordoa T, Juan-Fita M, Lopez Campos F, Perez-Fentes D, Vilaseca A, et al.
Future Oncol
. 2025 Mar;
:1-13.
PMID: 40029138
This review explores the complexities of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), emphasizing the limitations of using disease volume and metastatic timing as sole prognostic factors. Current algorithms...
9.
Michl M, Hagemeyer N, Looss M, Grebhardt S, Ringwald K, Potthoff K
Future Oncol
. 2025 Mar;
:1-8.
PMID: 40028796
www.clinicaltrials.gov identifier is NCT06607302.
10.
Nishimyo K, Ikeda S, Fushimi K, Yamazaki T, Ishikawa K
Future Oncol
. 2025 Feb;
:1-11.
PMID: 40018807
Background: Non-small-cell-lung cancer (NSCLC) medication use and guideline adherence remain unclear. We investigated treatment patterns and adherence among Japanese patients with NSCLC. Research Design And Methods: We analyzed treatment patterns...